Marquet Magda 4/A

What Happened
Magda Marquet, a director of First Tracks Biotherapeutics, was granted equity awards on May 12, 2026: 7,000 stock options and 2,500 restricted stock units (RSUs). The awards are reported as derivative grants (transaction code A) with $0.00 cash paid on the Form 4; these are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: May 12, 2026 (reported on Form 4; this filing is an amendment filed June 12, 2026 correcting the originally reported amounts; original Form 4 was filed May 14, 2026).
• Reported consideration: $0.00 (award/grant).
• Shares received: 7,000 stock options; 2,500 RSUs.
• Shares owned after transaction: not disclosed in the Form 4.
• Notable footnotes:
  • F1: Each RSU represents a contingent right to 1 share upon settlement for no consideration.
  • F2: RSUs vest 100% on the date of the Issuer's 2027 annual meeting, subject to continued service.
  • F3: Stock options vest 1/12 of total shares monthly beginning June 12, 2026 until fully vested, subject to continued service.
• Filing status: This is an amended Form 4 (filed 2026-06-12) correcting the amounts originally reported.

Context
These awards are standard equity compensation for a director and do not represent a market purchase or sale. RSUs will convert to shares (no cash required) only if and when they vest and are settled; the options vest over time and are subject to service conditions. The amendment updates the originally reported grant sizes—investors should rely on the corrected figures in this filing.